JPH1043274A - Infusion preparation - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain an infusion preparation having pH near the physiological level and needing no coloring preventing agent by accommodating a plastic infusion container containing a reducing sugar-contained medical fluid sterilized with carbon dioxide dissolved in a fluid with carbon dioxide absorbent in an oxygen impermeable facing container. SOLUTION: Carbon dioxide is dissolved in a medical fluid to lower the pH, and a plastic infusion container containing a reducing sugar-contained medical fluid is sterilized. The fluid container is accommodated with a carbon dioxide absorbent or with a free-oxygen absorber in the case of fatty emulsion reducing sugar mixed infusion in a wrapping container substantially impermeable to oxygen to surely prevent the generation of 5-hydroxymethyl-2-furfural(5-HMF) and the generation of free fatty acid. Thus, pH can be returned to pH before carbon dioxide dissolution in a short time, and the pH of a fluid can be set to the physiological pH range. Simultaneously, the generation of HMF can be prevented and the need of a coloring preventing agent can be eliminated.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a sterilized infusion preparation containing reducing sugar contained in a plastic infusion container.

[0002]

2. Description of the Related Art Conventionally, infusions have been administered to patients who are unable or inadequate for oral or tube feeding for the purpose of intravenous nutrition.

[0003] As such infusions, amino acid infusions containing essential amino acids, etc., electrolyte infusions containing minerals, sugar infusions containing reducing sugars, etc., and fat emulsions containing vegetable oils and the like are commercially available. Is used by mixing as appropriate according to the patient's symptoms, etc., but when using two or more infusions, there is a risk of causing bacterial contamination and the like at the time of mixing. There are problems such as complicated operations.

As a solution to the above problem, infusion preparations prepared by mixing two or more infusions in advance have been developed and marketed. However, infusion preparations using reducing sugars have a problem in that the reducing sugars are decomposed during sterilization and storage, and the decomposition products cause coloring of the infusion preparations. The drawback is that
In general, it can be improved by keeping the pH of the infusion solution low,
Considering that an infusion preparation is originally intended to be administered in a large amount in vivo, it is desirable that the pH of the preparation does not depart much from the pH of blood, and therefore it is not preferable to lower the pH too much. It is in.

[0005] For this reason, research and development of a reducing sugar-containing infusion preparation having a physiological pH close to the physiological pH have been eagerly desired in the art.

In the case of an infusion preparation containing a fat emulsion together with a reducing sugar, if the pH is adjusted to a low pH, there is a disadvantage that fatty acids in the fat emulsion are liberated and the quality is deteriorated. At present, the pH is adjusted to about 5 to 7.5 and, apart from this pH adjustment, a measure for adding a coloring inhibitor such as dithioglycerol or dithiothreitol is employed (for example, JP-A-5-9112). Etc.).

[0007] However, the addition and blending of components which are not related to nutritional supplementation, such as the coloring prevention agent, is not desirable in itself and should be avoided as much as possible. Further, the infusion preparation has a sulfur odor due to the coloring prevention agent. There is a disadvantage of doing so. Therefore, there is a strong need in the art for research and development of a reducing sugar-containing infusion preparation that does not use a coloring inhibitor, does not involve coloring due to the decomposition of reducing sugar, and can also suppress the production of free fatty acids.

[0008]

SUMMARY OF THE INVENTION An object of the present invention is to provide a color which is close to physiological pH and does not cause coloration due to decomposition of reducing sugars even without the use of a coloring inhibitor. The development and provision of a reducing sugar-containing infusion formulation that can be suppressed to an extent, and in the case of an infusion formulation containing a fat emulsion together with a reducing sugar, an improved stable infusion formulation that can further reliably suppress the production of free fatty acids. In developing and providing.

[0009]

SUMMARY OF THE INVENTION In view of the above circumstances, the present inventors have formulated a transfusion formulation containing a reducing sugar having a physiological pH and not using a coloring inhibitor, and particularly a transfusion formulation containing a reducing emulsion containing a fat emulsion. In the case of the above, keen research was conducted on technology for suppressing the production of free fatty acids.

As a result, the plastic infusion container (primary container), which is widely used, should be accommodated in this container.
In a chemical solution having a pH of about 0 to 8.0, add (before sterilization)
The solution is sterilized by dissolving the carbon dioxide gas to temporarily lower the pH of the solution, and then releases the carbon dioxide gas from the drug solution quickly by using a carbon dioxide gas absorbent to maintain the physiological pH. Infusion preparations that do not use a coloring inhibitor can be provided, and when the drug solution also contains a fat emulsion, any adverse effect of oxygen on the drug solution can be further prevented by using an oxygen absorber to provide any coloring inhibitor. Even without using, it has been found that the generation of decomposed products of reducing sugars is suppressed during sterilization and storage, and as a result, coloring is suppressed or prevented, and the generation of free fatty acids is surely suppressed.
The present invention has been completed based on this new finding.

That is, according to the present invention, a plastic infusion container containing a reducing sugar-containing drug solution sterilized in a state in which carbon dioxide is dissolved in the solution (hereinafter referred to as a "primary container").
Together with a carbon dioxide absorbent and, if the above-mentioned chemical solution also contains a fat emulsion, together with an oxygen absorbent, an outer container which is substantially impermeable to oxygen (hereinafter referred to as "secondary container")
The present invention provides an infusion preparation (reducing sugar-containing infusion preparation) characterized by being contained in an infusion preparation.

According to the present invention, more specifically, an infusion preparation containing a reducing sugar (hereinafter, referred to as an "infusion preparation containing an electrolyte and a reducing sugar") wherein the drug solution containing the reducing sugar further contains an electrolyte;
In particular, an infusion formulation containing an electrolyte-reducing sugar in which the carbon dioxide absorbent is an aqueous solution of an alkali metal hydroxide and / or an alkaline earth metal hydroxide, more preferably an aqueous solution of sodium hydroxide, and a drug solution containing a reducing sugar are further included. Infusion preparation containing fat emulsion (hereinafter referred to as "fat emulsion addition reducing sugar-containing infusion preparation"), in particular, a lipid emulsion addition reducing sugar-containing infusion preparation containing a primary container and a carbon dioxide absorbent in addition to a deoxidizer in a secondary container Is provided.

In the infusion solution of the present invention, the pH of the drug solution after dissolving carbon dioxide gas is in the range of 3.5 to 6.5, particularly, the infusion solution containing electrolyte-reducing sugar, and the pH of the drug solution after dissolving carbon dioxide gas is 4 to 6.5. An infusion formulation containing a fat emulsion and a reducing sugar in the range of 6.5 is preferred.

The pH of each of the infusion preparations before dissolution of carbon dioxide and after sterilization is preferably in the range of 5.0 to 8.5. Particularly, the infusion preparation containing a fat emulsion and a reducing sugar is preferably used. In this case, the pH of the drug solution before dissolving carbon dioxide and after sterilization is 5.
It is preferably in the range of 0 to 7.5.

Further, according to the present invention, it is more preferable that the reducing sugar is at least one selected from glucose, fructose and maltose, an infusion preparation containing reducing sugar; An infusion formulation containing a reducing sugar, the coloring of which is suppressed by the generation inhibition; and the production of free fatty acids during the storage is suppressed by suppressing the generation of a decomposition product of the reducing sugar during the dissolution of carbon dioxide gas and during storage. An infusion preparation containing a fat emulsion and a reducing sugar is provided.

[0016]

BEST MODE FOR CARRYING OUT THE INVENTION The infusion preparation containing a reducing sugar according to the present invention has a physiological pH by using the above specific carbon dioxide gas and the use of a carbon dioxide gas absorbent, and eliminates the need for an anti-coloring agent. In the case of an infusion formulation containing a reducing sugar, the coloring due to the decomposition of the reducing sugar is suppressed or prevented without adding a coloring inhibitor, and the generation of free fatty acids is further suppressed based on the use of an oxygen absorber. The biggest feature is that, in the case of an infusion formulation containing electrolyte-reducing sugar,
When containing the aqueous solution like carbon dioxide absorbent in the secondary vessel, HCO ₃ present in the electrolyte additive reducing sugar formulation infusion in the primary container ^- can accurately absorb the CO ₂ gas, as a result, carbonate The p of the infusion is lower than when the gas absorbent is solid.
It is also characterized in that H can be easily adjusted by an arbitrary value.

The preparation of the present invention has the following features except for the above-mentioned features.
It can be substantially the same as the conventional infusion preparation containing this kind of reducing sugar.

That is, in the preparation of the present invention, in the infusion preparation containing electrolyte-reducing sugar, a common electrolyte such as sodium bicarbonate, potassium bicarbonate, sodium chloride,
Electrolytes such as potassium chloride, calcium chloride, magnesium chloride, sodium lactate, sodium hydrogen phosphate, and sodium citrate can be used.

Further, the infusion preparation containing electrolyte-reduced sugar is required to contain bicarbonate ions. In other words, the infusion preparation contains an aqueous carbon dioxide absorbent in the above-mentioned secondary container. The amount of the carbon dioxide absorbent in the case of absorbing HCO ₃ ^- as CO ₂ gas therein can be calculated from a graph (FIG. 1) shown in a test example described later, and is a solid carbon dioxide absorbent. The pH of the infusion can be maintained at a physiological pH value more easily than in the case of (1).

As the fat emulsion used in the present invention, any of various known emulsions can be used. The oils and fats used for this may also be conventional ones, for example, vegetable oils such as soybean oil, cottonseed oil, safflower oil, corn oil, coconut oil, perilla oil, perilla oil, and fish oils such as cod liver oil For example, panassate (manufactured by NOF Corporation),
Medium-chain fatty acid triglycerides such as ODO (manufactured by Nisshin Oil Co., Ltd.), for example, chemically synthesized triglycerides (Chemic) such as 2-linoleoyl-1,3-dioctanoylglycerol and 2-linoleoyl-1,3-didecanoylglycerol.
al defined triglycerides) and the like can be used alone or in combination of two or more. The emulsifier used for the fat emulsion may also be one or two or more commonly used in pharmaceutical preparations. Examples thereof include egg yolk phospholipids, hydrogenated egg yolk phospholipids, soybean phospholipids, hydrogenated Examples include soybean phospholipids and nonionic surfactants such as "Pluronic F68" and "HCO-60" (both are trade names).

Further, the reducing sugar used in the infusion preparation of the present invention may be various commonly used ones, and preferable examples thereof include glucose, fructose, and maltose. It is not necessary to use only one kind of these reducing sugars alone, and two or more kinds can be used in combination.

A mixed infusion solution (chemical solution) containing the above-mentioned electrolyte or fat emulsion and reducing sugar is easily prepared by simply mixing the two, and the reducing sugar is added and mixed in advance after preparing the electrolyte or fat emulsion. Or at the time of preparing an electrolyte or a fat emulsion.

It is important that the method of sterilizing the chemical solution thus obtained is carried out in a state in which carbon dioxide is dissolved in the chemical solution and the pH thereof is lowered, and other operating conditions, such as sterilization time and sterilization temperature, are used. And the like can be the same as the usual sterilization operation conditions of this kind. More preferably, the sterilization is performed at a temperature of, for example, 102 to 121 ° C. for 20 minutes.
This is done by heating for ~ 60 minutes.

For dissolving and preparing carbon dioxide in the above-mentioned chemical solution, for example, typically, a space in a preparation tank containing the chemical solution is pressurized with carbon dioxide gas to obtain a desired pH, and
Mixed gas with a carbon dioxide rate in equilibrium with
(Air-carbon dioxide gas) or carbon dioxide gas alone, or by maintaining the pH at normal pressure. Thereafter, the drug solution is filled into a plastic infusion container, for example, a primary container such as an infusion bag or an infusion bottle, and the space thereof is replaced with a similar mixed gas or carbon dioxide gas, followed by high-pressure steam sterilization, hot water sterilization, and hot water shower. By performing sterilization or the like, a desired sterilization operation can be completed.

The pH value is not particularly limited as long as the decomposition of the reducing sugar by the sterilization operation can be suppressed.
Usually, it is preferably in the range of about 3.5 to 6.5 in the case of a reducing sugar-containing infusion such as an electrolyte-containing reducing sugar-containing infusion, or in the range of about 4 to 6.5 in the case of a fat emulsion-containing reducing sugar-containing infusion. It is better to be.

According to the sterilization method, the carbon dioxide dissolved in the chemical solution is gradually released from the chemical solution during and after the sterilization operation, and the plastic infusion container containing the chemical solution is generally used. As described above, in the case of packaging in a gas-barrier secondary container, its complete release becomes considerably difficult, and the pH of the drug solution remains inclined toward the acidic side for a very long time. Therefore, 5-HMF derived from reducing sugar
(5-Hydroxymethyl-2-furfural, 5-Hydr
oxymethyl-2-furfural) is likely to be produced, and in the case of an infusion containing a fat emulsion and a reducing sugar, the possibility of producing free fatty acids increases.

In the present invention, in order to surely avoid the possibility of the production of 5-HMFs and the production of free fatty acids, the sterilized plastic infusion container containing a drug solution is used together with a carbon dioxide gas absorbent, In the case of the emulsion-containing reducing sugar-containing infusion solution, it is further contained in a packaging container substantially impermeable to oxygen together with an oxygen scavenger. Thereby, the pH of the drug solution can be returned to the pH before dissolving carbon dioxide gas in a short time, and as a result, the pH of the solution is brought to a physiological pH range (about 5.0).
To 7.5), and 5 based on the acidification of the liquid.
-The risk of HMF production and free fatty acid production can be avoided.

On the other hand, in the case of an infusion preparation containing an electrolyte-added reducing sugar, the pH before dissolving carbon dioxide gas may exceed 8 in some cases.
For this reason, as in the case of the infusion preparation containing a fat emulsion and a reducing sugar, returning to the pH before the dissolution of carbon dioxide gas exceeds the physiological pH range, which may be undesirable. In the present invention, in such a case, an aqueous solution of an alkali metal hydroxide and / or an alkaline earth metal hydroxide is housed in a gas permeable container as a carbon dioxide absorbent, and this is housed in a secondary container together with the primary container. A desired pH can be maintained by appropriately selecting the amount of the carbon dioxide absorbent. This is based on the fact that there is a certain correlation between the pH of the chemical solution and the amount of the carbon dioxide absorbent in the aqueous solution state, whereby the pH of the chemical solution is lower than that before dissolving the carbon dioxide gas. Can be maintained.

Further, in the infusion preparation containing a fat emulsion and a reducing sugar of the present invention, by simultaneously containing an oxygen scavenger in the secondary container, adverse effects on the drug solution due to oxygen entering through the secondary container can be prevented. Thus, the production of the free fatty acid can be more reliably suppressed or prevented, and the decomposition of the reducing sugar can be more reliably suppressed.

In the infusion preparation of the present invention, the materials of the plastic infusion container (primary container) for accommodating the drug solution and the container for accommodating the carbon dioxide absorbent in an aqueous solution state are those of various gases conventionally used for pharmaceutical containers and the like. It can be a permeable plastic. Specific examples thereof include, for example, polyethylene, polypropylene, polyvinyl chloride, cross-linked ethylene / vinyl acetate copolymer, ethylene / α-olefin copolymer, blends of these polymers, laminates of these polymers (multi-layers). )).

The secondary container and the material thereof which are substantially impermeable to oxygen may be the same as those of gas barrier properties which have been well known in the past. Examples of the material include polyethylene terephthalate (PET) and polyethylene naphthalate. Phthalate (PEN), ethylene-vinyl alcohol copolymer (EVOH), polyvinylidene chloride (PVD)
C), nylon, polyester and the like. The secondary container is made of any of these materials or is formed of a film or sheet containing the same, a laminate of such films or sheets, silica or the like film or sheet,
Laminates, multilayer films, etc. of those deposited with alumina etc.
Preferably, it is made of a multilayer film.

Incidentally, "substantially does not transmit oxygen" means that
Usually, the oxygen permeability is about 10 ml / m ² · day or less, more preferably about 1 ml / m ² · day or less.

The carbon dioxide gas absorbent may be any of various known ones, for example, any commercially available carbon dioxide absorbent having an ability to absorb carbon dioxide. Specific examples thereof include E200 and E40.
0, E500 (both manufactured by Mitsubishi Gas Chemical Company), etc., and when the infusion formulation is an infusion formulation containing an electrolyte-reducing sugar containing bicarbonate ions, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide. And aqueous solutions of alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide, etc., which are used in a gas-permeable plastic container. The carbon dioxide gas absorbent is not particularly limited in its use form. For example, in the case of a liquid form or a fine particle form such as a powdered product, a necessary amount can be put in a permeable small bag or the like, and used. In the case of a molded article such as a sphere or a rod, it can be used in a small bag as described above, or can be used as it is.

The amount of the carbon dioxide gas absorbent used is sufficient to have a carbon dioxide gas absorption capacity of usually 500 ml per 700 ml of the liquid in the bag. Further, in the case of an infusion formulation containing an electrolyte-reducing sugar using a liquid carbon dioxide absorbent, it may be a predetermined amount calculated to have a desired pH,
This used amount can be calculated, for example, based on the calibration curve of FIG.

Further, the oxygen scavenger used in the infusion preparation containing a fat emulsion and a reducing sugar may be any of various conventionally known oxygen absorbing agents. Preferred examples thereof include those containing an iron compound such as iron hydroxide, iron oxide or iron carbide as an active ingredient. In particular, commercially available products of the above oxygen scavenger that can be advantageously used in the present invention include:
For example, "Ageless" (manufactured by Mitsubishi Gas Chemical Company), "Modulan" (manufactured by Nippon Kayaku), "Sequel" (manufactured by Nippon Soda Co., Ltd.) and the like can be exemplified.

The above-described oxygen absorber can be housed in a secondary container together with a plastic infusion container and a carbon dioxide absorbent, either as it is or in a form permeable to a small bag or the like, depending on its form. The amount used is sufficient to have an oxygen absorption capacity of 200 ml with respect to 700 ml of the liquid in the primary container.

Further, the carbon dioxide absorbent and the oxygen absorber are housed (enclosed) in the housing container separately from the primary container, that is, in the space between the secondary container and the primary container. As long as they are not individually housed, they can be used, for example, in a form in which both are mixed and put in one small bag.

Thus, the infusion product of the present invention can be obtained. This can be utilized in the same manner as a conventional infusion preparation of this type. For example, the secondary container is opened, and the contained infusion agent is used alone or, if necessary, mixed with other amino acid preparations or the like, and administered intravenously to a patient in need thereof. It can provide nutritional supplementation and the like.

[0039]

EXAMPLES Hereinafter, the present invention will be described in more detail by way of examples, but the present invention is not limited thereto.

[0040]

Example 1 300 ml of Ringer's bicarbonate solution having the following formulation was prepared.

Bicarbonate-containing solution (mg / ml) Sodium bicarbonate 2.268 mg Sodium chloride 6.721 mg Potassium chloride 0.298 mg Calcium chloride (dihydrate) 0.221 mg Lactic acid 0.500 mg Glucose 50.000 mg Prepared above The solution (pH = 7.1) was adjusted to pH 6.0 by bubbling carbon dioxide gas, and then the average thickness was 250 μm.
m in a polyethylene bag (primary container)
The solution was autoclaved at 6 ° C. for 40 minutes.

On the other hand, 1N aqueous sodium hydroxide solution, 2N aqueous sodium hydroxide solution and 4N
1 ml of each aqueous sodium hydroxide solution was accommodated in a bag (20 mm long, 35 mm wide) made of a laminated film made of 20 μm-thick polypropylene and 30 μm-thick polyethylene on the outside, and the inside was sealed as much as possible.

The above primary container and a bag made of a laminated film containing each carbon dioxide absorbent were packed in a bag made of a gas barrier laminated film (outside: nylon (thickness: 15 μm).
m) / polyvinyl alcohol (thickness 12 μm) / LLD
PE (thickness: 40 μm): inner side (secondary container, space in container: 300 ml), equilibrated in a thermostat at 25 ° C.
Five days later, the pH of the drug solution was measured.

The results obtained are shown in Table 1 below. FIG. 1 is a graph showing the relationship between the pH and the absolute amount of the carbon dioxide absorbent obtained from the above test results (vertical axis: pH, horizontal axis: absolute amount of carbon dioxide absorbent (sodium hydroxide: mmol amount)). Shown in

[0045]

[Table 1]

From FIG. 1, the absolute amount of carbon dioxide absorbent (x)
Indicates a high correlation (correlation coefficient = 0.9) where y is the pH value.
996), it can be seen that it is located on a straight line that satisfies the expression y = 0.01470x + 6.765.

[0047]

Example 2 Purified soybean oil, purified egg yolk lecithin, glucose and organic acid (succinic acid) were added to distilled water for injection according to the following formulation, and the mixture was subjected to coarse emulsification at 70 ° C. for 30 minutes using a TK homomixer. Perform fine emulsification with a Gorin homogenizer (400 kg / cm ² , 10 passes),
An emulsion was obtained. Then, the pH of the solution was adjusted to 6.0 using a 1N aqueous solution of sodium hydroxide to prepare a chemical solution having a final volume of 10 liters.

<Prescription> Purified soybean oil 44.4 g / l Purified egg yolk lecithin 6.66 g Dextrose 114.3 g Succinic acid 0.2 g Sodium hydroxide (pH adjuster) Appropriate amount Injected distilled water Appropriate amount The space was pressurized with carbon dioxide to adjust the liquid pH to 5.2. Thereafter, a mixed gas (carbon dioxide: nitrogen gas = 45: 5) having a carbon dioxide rate that is in equilibrium with the liquid pH is applied to the space.
In step 5), the above pH was maintained, and an infusion bag (made of polyethylene, film thickness 250 μm, content 1000 ml) was filled with 700 ml per bag, and the space of the bag was replaced with a similar mixed gas and put into a high-pressure steam sterilization vessel. The solution was sterilized at 110 ° C. for 40 minutes to obtain an infusion bag.

Next, the infusion bag was cooled, and then cooled together with “E500” (carbon dioxide absorbent manufactured by Mitsubishi Gas Chemical Company).
And “Ageless ZH200” (manufactured by Mitsubishi Gas Chemical Company, oxygen absorbent) in a four-layer multilayer film packaging container made of nylon / Evar / nylon / linear low-density polyethylene (LLDPE) (contents 1500 to 1600 ml).
To obtain an infusion preparation of the present invention.

The product thus obtained is stored at room temperature of 25 ° C. and 60% of humidity for 18 days, and the pH of the internal infusion is changed over time.
And the change of the amount of carbon dioxide in the bag was observed.

The results are as shown in Table 2 below.
Table 2 also shows the pH and the amount of carbon dioxide before sterilization of the tested infusion bags.

In addition, Table 2 was prepared in the same manner except that the above “E500” was not accommodated (“Ageless ZH20”).
Comparative infusion preparation I containing only "0" together with an infusion bag)
Replace the space in the preparation tank and the space in the infusion bag during sterilization with nitrogen gas only (do not use carbon dioxide gas)
The same result is also given for the comparative infusion preparation II in which only the “Ageless ZH200” was housed together with the infusion bag without containing the “E500”.

[0053]

[Table 2]

From Table 2, it can be seen that in the infusion preparation of the present invention, carbon dioxide gas almost disappeared in about 10 days, and the pH was reduced to the original pH.
It is clear that this rises to near, thus suppressing the production of free fatty acids over time.

[Brief description of the drawings]

FIG. 1 shows the pH of a drug solution obtained in a test according to Example 1.
4 is a graph showing a quantitative relationship between the carbon dioxide gas absorbent and the carbon dioxide absorbent.

──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. ⁶ Identification number Agency reference number FI Technical indication A61K 31/70 ADD A61J 1/00 390T (72) Inventor Rika Hamamoto Taro Yasuru Kitajima-cho, Itano-gun, Tokushima Prefecture 27-2, Niibori (72) Inventor Akiyo Abe 194-1 Oejima, Okuwashima, Naruto-shi, Tokushima Pref. 72) Inventor Masatoshi Inai, 554-1, Oji-gun, Dosei-cho, Itano-gun, Tokushima (72) Inventor Seiichiro Iguchi 87-5 Hamata Nishi, Saida, Naruto-cho, Naruto, Tokushima 34-1, Tainohamanishinishi, Kitajimacho Floral Heights No.1,201

Claims (13)

[Claims] 1. A plastic infusion container containing a chemical solution containing reducing sugar sterilized in a state in which carbon dioxide gas is dissolved in a liquid together with a carbon dioxide gas absorbent in an outer container that is substantially impermeable to oxygen. An infusion preparation characterized by the following. 2. The infusion preparation according to claim 1, wherein the drug solution containing a reducing sugar further contains an electrolyte. 3. The infusion preparation according to claim 2, wherein the carbon dioxide gas absorbent is an aqueous solution of an alkali metal hydroxide and / or an alkaline earth metal hydroxide. 4. The infusion preparation according to claim 3, wherein the carbon dioxide absorbent is an aqueous sodium hydroxide solution. 5. The infusion preparation according to claim 1, wherein the drug solution containing a reducing sugar further contains a fat emulsion. 6. The infusion preparation according to claim 5, wherein an oxygen absorber is further contained in the outer container, in addition to the plastic infusion container and the carbon dioxide absorbent. 7. The pH of the chemical solution after dissolving carbon dioxide gas is 3.5 to 3.5.
The infusion preparation according to any one of claims 2 to 4, which is in a range of 6.5. 8. The pH of a chemical solution after dissolving carbon dioxide gas is 4 to 6.5.
The infusion preparation according to claim 5 or 6, wherein 9. The infusion preparation according to claim 1, wherein the pH of the drug solution before dissolution of carbon dioxide and after sterilization is in the range of 5.0 to 8.5. 10. The pH of a drug solution before dissolving carbon dioxide and after sterilization.
Is in the range of 5.0 to 7.5.
The infusion preparation according to any one of the above. 11. The infusion preparation according to claim 1, wherein the reducing sugar is at least one selected from glucose, fructose and maltose. 12. The infusion preparation according to any one of claims 1 to 11, wherein coloring is suppressed by suppressing generation of a decomposed product of reducing sugar during dissolution and storage of carbon dioxide gas. 13. The method according to claim 1, wherein coloration is suppressed by suppressing generation of decomposed products of reducing sugars during dissolution of carbon dioxide gas and during storage, and generation of free fatty acids during storage is suppressed.
2. The infusion preparation according to any one of 1.